LINK-002
Asset
Inhibits necrosis to extend cell viability and enable tissue engineering.
- Stage
- Preclinical
- Modality
- Not known
- Target
- Not known
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Lab reagent market
Preclinical, linkgevity.com, 10 Oct 2026
Tissue engineering
Preclinical, linkgevity.com, 10 Oct 2026
In the full profile
- Owner and partners1
Every asset’s record: target, stage, trials and the evidence behind it.